Open AccessNovel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis
Author(s) -
Einat Almon,
Yoseph Shaaltiel,
Wisam Sbeit,
Alex Fich,
Doron Schwartz,
Mattitiahu Waterman,
Mali Szlaifer,
Hadar Reuveni,
Bat-Chen Amit-Cohen,
Sari Alon,
Raul Chertkoff,
Alona Paz,
Yaron Ilan
Publication year - 2020
Publication title -
journal of clinical gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.141
H-Index - 112
eISSN - 1539-2031
pISSN - 0192-0790
DOI - 10.1097/mcg.0000000000001314
Subject(s) - medicine , ulcerative colitis , calprotectin , gastroenterology , oral administration , clinical trial , immune system , randomized controlled trial , immunology , inflammatory bowel disease , disease
OPRX-106 is an orally administered BY2 plant cell-expressing recombinant TNF fusion protein (TNFR). Oral administration of OPRX-106 was shown to be safe and effective in inducing favorable anti-inflammatory immune modulation in humans. The current study was aimed at determining the safety and efficacy of OPRX-106 in patients with ulcerative colitis (UC).